Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information



Palo Alto Office
525 University Avenue
Suite 610
Palo Alto, CA, 94301
Waltham Office
303 Wyman Street
Suite 300
Waltham,, MA, 02451-1208


Managing Director
Managing Director
Managing Director


Skyline Ventures

Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies. Their areas of expertise include small molecule and protein therapeutics; medical devices; diagnostics; and technologies that facilitate drug discovery and life science research.

They all have MD or PhD degrees, and hands-on operating experience in various start-up healthcare companies that later went public. As a result, they are known for the value they offer their companies, as board members and shareholders. They are also known for being fundamental, extremely patient investors.

The days when momentum investing drove the public biotechnology markets are long gone, and they are glad that they are. The public markets demand data, not dreams. As a result, it is data that drives their decision process. In considering a new investment, they focus on whether there is adequate proof of principle to believe that the company’s products will work.

In therapeutics, for example, they look closely at whether the biochemistry, animal models and any human data make it more probable than average that the product will eventually prove to have an important therapeutic benefit. The size of the potential market and the quality of the management or founding team are critical in their evaluation as well.

Skyline Ventures are value and return driven, more than driven by the stage of the investment. Most often they lead or co-lead a company’s first or second institutional venture round, but have previously helped found companies and invested in PIPEs and leveraged buyouts.

In October 2007, they completed raising Skyline V, which has $350 million in committed capital. They have approximately $800 million under management. They target investments of $15-35 million per portfolio company over the life of the company.

Recent Milestones


Company Date Round Size Participants
Sutro Biopharma 12/2013Series D$26M6
Dicerna Pharmaceuticals 7/2013Series C$60M9
Crescendo Bioscience 1/2013Series D$28M5
Genocea Biosciences 10/2012Series C$30M10
Sutro Biopharma 5/2012Series C$16.5M5
Collegium Pharmaceutical 2/2012Venture Round$22.5M2
SI-BONE 9/2011Venture Round$16M2
Genocea Biosciences 1/2011Series B$35M9
Sutro Biopharma 11/2010Series C$36.5M5
SI-BONE 8/2010Series B$10.6M1
Tetraphase Pharmaceuticals 6/2010Series C$45M6
Calibra Medical 11/2009Venture Round$1.4M5
Calypso Medical 11/2009Series E$50M4
Proteon Therapeutics 5/2009Series B$50M8
SpinalMotion 2/2009Series C$500k4
Tetraphase Pharmaceuticals 8/2008Series A$15M5
InteKrin 8/2008Series C$18.5M7
NovaSys 5/2008Venture Round$49.5M10
Concert Pharmaceuticals 4/2008Series C$37M12
Proteon Therapeutics 9/2007Series A$12M4
Satiety 7/2007Series D$30M6
MAP Pharmaceuticals 3/2007Series D$50M6
Concert Pharmaceuticals 11/2006Series B$48.5M8
Concert Pharmaceuticals 7/2006Series A$10M5
Avidia 5/2006Series C$43.8M7
KAI Pharmaceuticals 5/2006Series B$35M7
Sirtris Pharmaceuticals 12/2004Series A$13M5
Applied Genetics Technologies Corporation 11/2003Series B$27M4



  1. Sutro Biopharma Secures $26M in Series D Financing ( [edit]
  2. Dicerna Pharmaceuticals Raises $60M In Series C Financing ( [edit]
  3. Crescendo Bioscience Raises $28M to Sell Arthritis-Tracking Blood Tests ( [edit]
  4. Genocea raises $30M to advance herpes vaccine ( [edit]
  5. Sutro Closes $16.5 Million Second Tranche of Series C Financing ( [edit]
  6. Collegium collects $22.5M in new fundraise ( [edit]
  7. SI-BONE Closes $16.0M Financing Round ( [edit]
  8. Genocea Biosciences Closes $35M Series B Financing Round ( [edit]
  9. Sutro Biopharma Secures $36.5M in Series C Financing ( [edit]
  10. Si-Bone, Inc.: Series B $10.6M ( [edit]
  11. Tetraphase hauls in $45M C round to back antibiotic work ( [edit]
  12. Calibra takes $1.4M to for insulin delivery devices ( [edit]
  13. Calypso Medical Technologies, Inc.: Series E $50M ( [edit]
  14. Proteon Therapeutics Completes Second Closing of Equity Financing ( [edit]
  15. VentureBeat ( [edit]
  16. Equity Help Desk ( [edit]
  17. InteKrin raises $18.5M for continued work on diabetes drug ( [edit]
  18. Novasys Medical takes $49.5M for women’s medical device ( [edit]
  19. Capital Funding Report [edit]
  21. Satiety pulls in $30M for obesity device ( [edit]
  22. MAP Pharma raises $50M for respiratory and CNS disease treatments ( [edit]
  23. Concert Pharmaceuticals Raises $48.5 Million in Series B Financing ( [edit]
  24. Concert Pharmaceuticals, Inc.,â„¢ Announces Financing of its Series A Round ( [edit]
  26. KAI Pharmaceuticals Completes $35 Million Series B Financing ( [edit]
  27. Sirtris closes $13 million financing ( [edit]
  28. Company Overview ( [edit]
Edit This Page
Last Edited 3/7/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy